InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
February 17, 2023 17:00 ET
|
InMed Pharmaceuticals Inc.
Closed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research using rare cannabinoids in treating glaucoma and...
InMed Submits Form 12b-25
February 09, 2023 21:41 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
InMed Provides Business Update and Milestones for 2023
January 10, 2023 07:30 ET
|
InMed Pharmaceuticals Inc.
Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in...
InMed Announces Results of 2022 Annual General Meeting
December 15, 2022 18:17 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
December 12, 2022 18:47 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
November 21, 2022 17:00 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
November 18, 2022 08:00 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
InMed Provides Update on Management Changes
November 17, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
November 16, 2022 07:00 ET
|
InMed Pharmaceuticals Inc.
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’sIdentified two lead cannabinoid analog compounds for in vivo studiesNSERC grant funding supports InMed’s...
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
November 11, 2022 18:51 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...